[1] Zhou B, Perel P, Mensah GA, et al., 2021, Global epidemiology, health burden, and effective interventions for elevated blood pressure and hypertension. Nature Reviews Cardiology, 18(11): 785-802. [2] Mills KT, Stefanescu A, He J, 2020, The global epidemiology of hypertension. Nature Reviews Cardiology, 16(4): 223-237. [3] Kearney PM, Whelton M, Reynolds K, et al., 2005, Global burden of hypertension: analysis of worldwide data. Lancet, 365(9455): 217-223. [4] Zhao L, Mason NA, Morrell NW, et al., 2001, Sildenafil inhibits hypoxia-induced pulmonary hypertension. Circulation, 104(4): 424-428. [5] Gu D, Reynolds K, Wu X, et al., 2002, Prevalence, awareness, treatment, and control of hypertension in china. Hypertension, 40(6): 920-927. [6] Humbert M, Yaici A, Groote PD, et al., 2014, Screening for pulmonary arterial hypertension in patients with systemic sclerosis: clinical characteristics at diagnosis and long-term survival. Arthritis Rheum, 63(11): 3522-3530. [7] Fadl Elmula FE, Hoffmann P, Larstorp AC, et al., 2014, Adjusted drug treatment is superior to renal sympathetic denervation in patients with true treatment-resistant hypertension. Hypertension, 63(5): 991-999. [8] Ke B, Zhu N, Luo F, et al., 2017, Targeted inhibition of endoplasmic reticulum stress: New hope for renal fibrosis (Review). Molecular Medicine Reports, 16(2): 1014-1020. [9] Mondal B, Samsuzzaman M, Das S, 2023, Access to chronic kidney disease (CKD) care: Its barriers and facilitators in a community development block in Purba Bardhaman, West Bengal: A qualitative study. Journal of Family Medicine and Primary Care, 12(8): 1636-1643. [10] Papadopoulos DP, Makris TK, Papazachou U, et al., 2008, Antiendothelial cell antibody levels in patients with masked hypertension. International Journal of Cardiology, 130(3): 405-408. [11] Okano H, Masuda H, Ohkubo C, 2005, Decreased plasma levels of nitric oxide metabolites, angiotensin II, and aldosterone in spontaneously hypertensive rats exposed to 5 mT static magnetic field. Bioelectromagnetics, 26(3): 161-172. [12] Scialla JJ, Astor BC, Isakova T, et al., 2013, Mineral metabolites and CKD progression in African Americans. Journal of the American Society of Nephrology, 24(1): 125-135. [13] Seryapina AA, Shevelev OB, Moshkin MP, et al., 2017, Stress-sensitive arterial hypertension, haemodynamic changes and brain metabolites in hypertensive ISIAH rats: MRI investigation. Experimental Physiology, 102(5): 523-532. [14] Nowak KL, Kakkar R, Devalaraja M, et al., 2020, A phase 1 randomized dose-escalation study of a human monoclonal antibody to IL-6 in CKD. Kidney360, 2(2): 224-235. [15] Anderson AH, Xie D, Wang X, et al., 2021, Novel risk factors for progression of diabetic and nondiabetic CKD: Findings From the Chronic Renal Insufficiency Cohort (CRIC) Study. American Journal of Kidney Diseases, 77(1): 56-73. [16] Cheng T, Yun Z, Fan S, et al., 2024, Causal association between blood metabolites and risk of hypertension: a Mendelian randomization study. Frontiers in Cardiovascular Medicine, 11: 1373480. [17] Davey Smith G, Lawlor DA, Harbord R, et al., 2005, Association of C-reactive protein with blood pressure and hypertension: life course confounding and mendelian randomization tests of causality. Arteriosclerosis Thrombosis and Vascular Biology, 25(5): 1051-1056. [18] He WJ, Li C, Mi X, et al., 2020, An untargeted metabolomics study of blood pressure: findings from the Bogalusa Heart Study. Journal of Hypertension, 38(7): 1302-1311. [19] Hou Y, Xiao Z, Zhu Y, et al., 2024, Blood metabolites and chronic kidney disease: a Mendelian randomization study. BioMed Central Genomics, 17(1): 147. [20] Sinnott-Armstrong N, Tanigawa Y, Amar D, et al., 2021, Genetics of 35 blood and urine biomarkers in the UK Biobank. Nature Genetics, 53(2): 185-194. [21] Butler-Laporte G, Kreuzer D, Nakanishi T, et al., 2020, Genetic determinants of antibody-Mediated immune responses to infectious diseases agents: a genome-wide and HLA association study. Open Forum Infectious Diseases, 7(11): ofaa450. [22] Watanabe S, Konta T, Ichikawa K, et al., 2019, The association between urinary sodium excretion and blood pressure in a community-based population: the Yamagata (Takahata) study. Clinical and Experimental Nephrology, 23(3): 380-386. [23] Hemani G, Zheng J, EIsworh B, et al., 2018, The MR-Basplatform supports systematic causal inference across the human phenome. Elife, 7: e34408. [24] Bowden J, Davey Smith G, Burgess S, 2015, Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger Regression. International Journal of Epidemiology, 44(2): 512-525. [25] Bowden J, Davey Smith G, Haycock PC, et al., 2016, Consistent estimation in mendelian randomization with some invalid instruments using a weighted median estimator. Genetic Epidemiology, 40(4): 304-314. [26] Slob EAW, Burgess S, 2020, A comparison of robust mendelian randomization methods using summary data. Genetic Epidemiology, 44(4): 313-329. [27] Gill D, 2020, Heterogeneity between genetic variants as a proxy for pleiotropy in mendelian randomization. JAMA Cardiol, 5(1): 107-108.